Takeda’s Active Pharmaceuticals Ingredient (API) manufacturing facility at Grange Castle, Clondalkin, Dublin, is now operational. The government, through IDA Ireland, supports the manufacturing facility. The facility currently employs 40 of the 60 planned employees. The facility manufactures active ingredients for diabetes and sleep disorder drugs.
Takeda also announced to integrate the two subsidiaries, at Grange Castle in Clondalkin and at Bray in Co. Wicklow, in order to achieve better operating synergies for the two.
Harney, Minister for Health and Children, said: “This facility is a significant and important investment from a leading Japanese company and its official opening is a further excellent development for the pharmaceutical sector in Ireland. It demonstrates Ireland’s continuing ability to attract and to successfully implement high value manufacturing investments and to provide the knowledgeable and skilled workforce required. I congratulate all at Takeda for this success,” as quoted by Biotechnology Ireland.
Takashi Inkyo, General Manager of Pharmaceutical Production Division at Takeda, said: “We are most grateful to IDA Ireland and South Dublin County Council for their strong support in establishing our second operation in Ireland at Grange Castle. This new multi-product plant and our pharmaceutical finished product operations in Bray form our overseas manufacturing base for Takeda strategic products with integrated facilities covering the complete process from active ingredient through to final solid oral dosage product,” as quoted by Biotechnology Ireland.